Effects of dose escalation on the safety and efficacy of Cabozantinib in patients with advanced/metastatic Renal Cell Carcinoma

Trial Profile

Effects of dose escalation on the safety and efficacy of Cabozantinib in patients with advanced/metastatic Renal Cell Carcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2018

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Mar 2018 New trial record
    • 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top